source
- Revolution Medicines secures FDA approval for Rasonque, a RAS inhibitor targeting advanced pancreatic cancerRevolution Medicines announced FDA approval of its RAS inhibitor Rasonque for patients with advanced pancreatic cancer, marking a milestone for the company. The approval is seen as a breakthrough…
- Cancer drug shortages persist, hampering patient care and highlighting lasting impacts of platinum chemotherapyThe STAT+ newsletter reports that cancer treatment centers continue to struggle with ongoing shortages of key oncology drugs, forcing clinicians to alter or delay therapy for patients. These short…